Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary
for their growth and may make them more sensitive to radiation therapy. Radiation therapy
uses high-energy x-rays to damage tumor cells. Giving tipifarnib together with radiation
therapy may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of tipifarnib when
given together with radiation therapy in treating patients with unresectable locally advanced
pancreatic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania University of Pennsylvania